Taiko Pharmaceutical Co Ltd
TSE:4574
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Taiko Pharmaceutical Co Ltd
TSE:4574
|
14.5B JPY |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.1T JPY |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.3B USD |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.2B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
122.1B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
11.6B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.9B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.1B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.2T KRW |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Taiko Pharmaceutical Co Ltd
Glance View
Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs. The company is headquartered in Osaka, Osaka-Fu and currently employs 264 full-time employees. The company went IPO on 2009-03-18. The firm is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Taiko Pharmaceutical Co Ltd is 14.4%, which is above its 3-year median of -25%.
Over the last 3 years, Taiko Pharmaceutical Co Ltd’s Net Margin has increased from -171% to 14.4%. During this period, it reached a low of -171% on Aug 30, 2022 and a high of 14.4% on Oct 30, 2025.
